



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_418_25

You asked:

I am analysing the usage of intra-vitreous injections or implants by the NHS. I would greatly appreciate if you could answer the following questions:

Our response:

Please see information provided below. Noting: Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

1. How many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2025:

Aflibercept	1089
Bevacizumab	20
Brolucizumab	0

Dexamethasone	46
Faricimab	1469
Fluocinolone acetonide	**
Ranibizumab – Lucentis	**
Ranibizumab – Biosimilar	0

2. Please provide the number of injections/implants by eye condition for the four-month period from May to August 2025:

Please note, we only capture some of the information requested in the table below. Additionally, the drugs listed are used to treat conditions other than those listed below so the totals for Parts 1&2 will not correlate.

Number of Injections/Implants: May to August 2025:

Treatment	Eye Conditions		
	Wet Age-Related Macular Degeneration (wAMD)	Diabetic Macular Oedema (DMO)	Retinal Vein Occlusion (RVO)
Aflibercept	586	138	355
Bevacizumab	Not monitored by condition		
Dexamethasone	Not Monitored for AMD	Not Monitored for DMO	**
Faricimab	948	381	38
Ranibizumab - Lucentis	**	**	**
Ranibizumab - Ongavia (Ongavia, Ximluci, Byooviz, Rimmyrah)	N/A	N/A	N/A